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Abstract
Existing vaccines are mainly limited to the microorganisms we are able to culture and produce and/or to those whose killing is 
mediated by humoral responses. It has been more difficult to develop vaccines capable to induce functional cellular responses 
needed to prevent or cure chronic diseases. Several results suggest that specific enhancement of T-cell responses is nevertheless 
possible in persistently infected patients to treat chronic diseases including cancer. This work presents preclinical and clinical 
results obtained using virus like particles (VLPs) as a vaccine platform. VLPs based on envelope, membrane or nucleocapsid 
microbial proteins are able to stimulate mucosal as well as systemic immunity and induce a strong immune response after nasal 
or systemic administration in mice, non human primates and humans. In addition, the immune response obtained is biased in a 
Th1 direction. VLPs were able to potentiate humoral and cellular immune responses against several viral and cancer antigens as 
measured by LPA and IFN-Ȗ ELISPOT assays. Studies in animals and humans with nasal and systemic formulations show that it 
is possible to induce functional immune responses against HBV, HCV, dengue as well as against prostate and cervical cancers. 
© 2010 Elsevier B.V. All rights reserved  
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1.   Introduction 
Virus-like particles (VLPs) are inert, empty viral capsids, which contain no DNA/RNA from the virus itself. 
However, they retain the structure of a virus particle and can be engineered to have antigens attached. By extension, 
particles that contain antigens from viral or non-viral sources and show similar size and shape as viruses are also 
regarded as VLPs. VLPs-displayed antigens are efficiently taken up by dendritic cells (DC) and induce potent 
immune responses after parenteral, mucosal or transcutaneous immunization [1-3]. 
 
Several strategies have been used to produce a given antigen with capacity to form VLPs, or to obtain it as part of a 
recombinant protein forming VLPs. Antigens repeated on VLPs, like those naturally found in viral capsids, 
efficiently cross-link B-cell receptors and, therefore, induce strong IgG responses. Recent studies have shown the 
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improvement in the immunogenicity of covalently coupled peptides from the allergen Der p 1 to a VLP derived 
from bacteriophage Qbeta (Qbeta-Der p 1), demonstrating that this strategy can be used to enhance the efficiency of 
allergen-specific immunotherapy and validate the approach in humans [4]. 
 
One of the most relevant examples of VLPs in the history of vaccinology has been the recombinant hepatitis B 
surface antigen (HBsAg), produced as VLPs in Saccharomyces cerevisiae or Pichia pastoris yeasts. It has been used 
for more than 20 years as a very effective vaccine in the prevention of Hepatitis B. More recently, in 2006, the U.S. 
Food and Drug Administration (FDA) approved a human papilloma virus (HPV) vaccine for clinical use, that 
consists of HPV 6, 11, 16, and 18 recombinant VLPs mixed with an aluminum-containing adjuvant. This was a very 
positive advancement in the use of VLPs for the development of new vaccines. 
 
2.   Virus-like particle technology in chronic hepatitis B immunotherapy 
The entire recombinant core antigen (HBcAg) of the hepatitis B virus (HBV) promotes Th1 immunomodulation of 
the immune response to coadministered antigens, including the HBV surface antigen (HBsAg), after subcutaneous 
[5] or nasal [6] inoculations. Riedl and coworkers have related this adjuvant activity to the nucleic acid content in 
the particle, which interacts with Toll-like receptor-3 (TLR3) [7]. In addition, we have observed a synergistic effect 
in the enhancement of the immunogenicity of both the surface and core antigens after nasal administration, 
indicating that HBcAg increases the anti-HBsAg response and that, conversely, HBsAg increases the specific anti-
HBcAg response [8]. 
 
These results led in 1998 to formulate a new VLP-based nasal therapeutic vaccine candidate for chronic hepatitis B 
therapy under the name NASVAC, that contained the surface and core HBV antigens (see Figure 1 below). The 
candidate vaccine induced stronger cellular and humoral (IgG2a) immune responses than a commercial HBsAg 
vaccine in mice. These results were in favour of the therapeutic use of the vaccine, as Th1-biased immune responses 
correlate with control of HBV [9, 10]. A double blinded, randomized and placebo-controlled Phase I clinical trial 
was therefore launched in healthy volunteers, evidencing safety and immunogenicity of this nasal vaccine candidate 
with a relatively low amount of antigen administered (50 ȝg each) [11]. This is the first nasal candidate vaccine 
developed for hepatitis B therapy, taking advantage of the cross-adjuvanting effect of the VLPs included in the 
formulation [5-8]. 
 
The concept of using mucosal immunization is a novel concept in therapeutic vaccination. Moreover, in the field of 
hepatitis B therapeutic vaccine development, this is the first candidate to include the hepatitis B nucleocapsid 
antigen as part of the formulation. Clinical trials in chronically infected patients are currently ongoing whose results 
are expected to be published by the end of 2010. 
 
 
 3.   Virus-like particle technology in Human Immunodeficiency Virus immunotherapy 
Cell-mediated immune responses to HIV-1are an essential component of viral replication control. In this regard, 
potent Th1 adjuvants are required to develop novel vaccine candidates. On the basis of previous evidence obtained 
in the NASVAC project, it was hypothesized that a mixture of the HBsAg and HBcAg VLPs would act as a Th1 
adjuvant. This led to the application of the concept to HIV research, where a soluble, multiepitopic antigen (named 
CR3) was developed that includes several Th and CTL epitopes from HIV-1antigens [12].  
 
In mice, the multiantigenic formulation comprising CR3, HBcAg and HBsAg induced detectable anti-CR3 cellular 
responses after nasal and parenteral inoculations. Best results were obtained in schedules that combined parenteral 
and nasal co-administrations [13,14]. A strong T helper cell (Th)-1 bias of the CR3-specific response was observed, 
together with the induction of CD4+ and CD8+ T cells in mice spleens and IFN-Ȗ-secreting cells in mesenteric lymph 
nodes. Additionally, we also detected anti-HBsAg and anti-HBcAg cellular and humoral responses. In this regard, 
our multiantigenic formulation might provide immunity to HBV as well, which would be of additional benefit 
considering the high HIV-HBV coinfection rate reported worldwide. Preliminary studies suggest that the adjuvant 
effect of HBV antigens on the CR3-specific immune response depends on the physical interaction among the 
proteins [13] and requires co-inoculation of the antigens [15]. Preclinical evaluation of this multiantigenic vaccine 
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candidate was conducted up to the demonstration of the safety and immunogenicity of the formulation. A clinical 
Phase I trial is planned to begin in 2010. 
 
In a second set of experiments, it was demonstrated that the coupling of multiantigenic peptides (MAPs) to HBsAg 
VLPs greatly improved the amplitude and crossreactivity of the resulting humoral immune response, opening a new 
window for the practical use of VLP structures as adjuvants in the field of HIV vaccines [16-18]. 
 
 
4. Very small size proteoliposome (VSSP) technology applied to cancer therapy 
 
A novel structure used as an adjuvant is a nanoparticulate hydrophobic conjugate in which purified gangliosides 
were incorporated into the outer membrane protein complex of Neisseria meningitidis to form Very Small Sized 
Proteoliposomes (VSSP), a type of small (9 nm) vesicles with strong adjuvanticity and antigen delivery properties 
[19]. Among the most remarkable properties of VSSP is their capacity to activate dendritic cells through the display 
of powerful danger signals, resulting in the enhancement of CTL and antibody responses to coadministered or 
inserted peptides and proteins. VSSPs also show strong capacity to prime CD8+ T cell responses without a need for 
CD4+  T cell help and offer the possibility to be used as an antigen delivery system [20]. 
 
VSSP adjuvant technology has been applied to the development of cancer therapy projects, specifically in the fields  
of therapeutic vaccines against Human Papillomavirus (HPV) and prostate cancer, using the antigen delivery system 
ability of VSSP to display heterologous peptides from HPV or GnRH, respectively [21, 22]. 
 
The formulation containing VSSP and the GnRH m1-TT peptide adjuvanted in Montanide ISA-51 was injected to 
prostate cancer patients in a Phase I clinical trial. It took four bi-weekly injections followed by three monthly 
injections to detect significant levels of antibodies to GnRH in all vaccinated patients, in spite of the immune 
tolerance to this self antigen. PSA and testosterone levels decreased to very low levels in the patients, even lower 
than castration levels (1.75 nM/L), and remained at such basal levels during a 25 months follow-up. Clinically, all 
patients remained with a normal prostate size and were free of serious urinary manifestations [22]. 
 
A therapeutic vaccine candidate against HPV using the VSSP adjuvant technology was evaluated in a mice tumor 
model using a CTL epitope of HPV [21]. A Phase I study was launched to apply this novel vaccine candidate to 
HPV-infected women with high degree cervical lesions. An important percentage of the patients evidenced virus 
clearance as determined by PCR and more than 50% of the lesions went into remission, suggesting that the 
treatment was both safe and effective [24]. 
 
 
5. Virus-like particle technology applied to dengue virus prevention 
VLPs from the recombinant dengue-2 capsid protein were obtained by submitting the recombinant protein produced 
in E. coli to an in vitro assembly reaction using single-stranded DNA. As a result, particles of around 30 nm were 
obtained independent of the specificity and the length of the oligonucleotide used (Figure 1) [24]. These VLPs were 
adjuvanted with alum and inoculated to mice. The animals did not show evidence for antiviral antibodies, but their 
splenocytes secreted high levels of IFNJ upon virus stimulation, and a significant protection rate was achieved after 
lethal challenge with dengue-2 virus. Both IFNJ secretion and protection against viral challenge were dependent on 
CD4+ and CD8+ T cells [25].  
 
In parallel, we also constructed a novel chimeric protein comprising the Domain III region of the envelope protein 
and the capsid protein from dengue-2 virus, in the hope to obtain a molecule potentially able to induce both humoral 
and cell-mediated immunity. The fusion protein was mixed with oligodeoxynucleotides to obtain particulate 
aggregates and tested in mice in comparison with non-aggregated control preparations.  
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Figure 1. Hepatitis B Virus virus-like particles a) HBsAg; b) HBcAg; c) NASVAC: formulation containing a 
mixture of HBsAg and HBcAg (1:1); d) Dengue virus VLPs comprising the nucleocapsid antigen. 
Although a similar humoral immune response was induced by both forms of the protein, the aggregated particles 
elicited a much stronger cellular immune response mediated by CD4+ and CD8+ T cells, as measured by in vitro 
IFNȖ secretion and by protection experiments [26]. When the two kinds of particulate antigens were mixed with an 
additional fusion protein containing epitopes from the envelope glycoprotein of dengue-4 virus, an increase in the 
protective immune response was obtained upon DEN-4 challenge of the immunized mice. All these results 
demonstrate the suitability of VLPs to induce a proper immune response against dengue virus.  
6. Virus-like particle technology applied to chronic hepatitis C immunotherapy 
The VLP technology is being used also in the development of a vaccine against hepatitis C virus. CIGB-230 is a 
vaccine candidate based on the mixture of a recombinant truncated HCV core protein, which is able to self-assemble 
into VLPs (27), and a plasmid for DNA immunization, pIDKE2, that expresses the HCV structural antigens (Core, 
E1, E2) of a HCV genotype 1b isolate [28]. The plasmid component induces both humoral and cellular immune 
responses against Core, E1 and E2, while the recombinant core protein mainly elicits antigen-specific CD4+ T cell 
responses [29, 30].  
 
After satisfactory pre-clinical studies, where CIGB-230 showed low toxicity in rodents [31], a Phase I clinical trial 
was carried out with fifteen HCV genotype 1b-infected patients who had remained non-responders to previous IFN 
+ Ribavirin therapy. The vaccine candidate was well tolerated and immunogenic in these difficult-to-treat HCV-
A
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chronically infected individuals [32]. Neutralizing antibody response against heterologous HCV pseudoparticles was 
modified in eight individuals, including six de novo responders. In addition, a significant increase in the number of 
individuals having detectable lymphoproliferative responses and IFN-Ȗ secretory responses against HCV structural 
antigens was observed during treatment. Most importantly, 46.7% of the individuals responded positively against 
more than one antigen present in the vaccine candidate, and more than 40% of the vaccinated individuals improved 
or stabilized their liver histology, particularly reducing fibrosis, which correlated with the de novo induction of a 
cellular immune response against more than one HCV antigen [33].  
 
The enhanced functional immune response observed after administration of the vaccine candidate CIGB-230 may be 
due to a synergistic action between its two components, plasmid and protein, perhaps due to the reduced degradation 
of plasmid DNA and to a better activation and antigen presentation by antigen presenting cells [34]. The CIGB-230 
vaccine candidate is currently in Phase II clinical trial in HCV-chronically infected individuals. 
 
7. Conclusions 
VLP technology has been widely explored at the Center for Genetic Engineering and Biotechnology, Cuba, 
evidencing the potentialities of such particles to promote immune responses due to their unique capacity to activate 
innate and adaptive immune responses. VLPs elicit a potent immune response against themselves and against 
homologous or heterologous antigens, which are coadministered with or inserted into the VLPs. VLPs can be 
exploited as a platform to increase the immunogenicity of poorly immunogenic antigens, including self proteins. 
 
All these features support the possible use of VLPs expressed in Pichia pastoris or E. coli as therapeutic and/or 
prophylactic vaccine candidates to deal with the immunotherapy of chronic diseases and cancer as well as to be 
applied to preventive settings in “difficult” sceneries as HCV, HIV and Dengue virus vaccine development. 
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